Fri, March 3, 2017
Thu, March 2, 2017
Wed, February 15, 2017
Mon, February 13, 2017
Wed, February 8, 2017
Thu, February 2, 2017
Fri, January 13, 2017
Wed, January 11, 2017
Wed, January 4, 2017
Fri, December 16, 2016
Thu, December 15, 2016
Mon, December 12, 2016
Thu, December 8, 2016
Wed, November 23, 2016
Mon, November 14, 2016
Sun, November 13, 2016
Wed, November 9, 2016
Thu, November 3, 2016
Wed, November 2, 2016
Mon, October 17, 2016
Sat, October 8, 2016
Thu, October 6, 2016
Wed, October 5, 2016
Mon, October 3, 2016
Fri, September 30, 2016
Thu, September 29, 2016
Tue, September 27, 2016
Mon, September 26, 2016
Fri, September 23, 2016
Thu, September 22, 2016
Wed, September 21, 2016
[ Wed, Sep 21st 2016 ] - Market Wire
Last Patient Out
Tue, September 20, 2016
Mon, September 19, 2016
Sun, September 18, 2016
Fri, September 16, 2016
Thu, September 15, 2016
Wed, September 14, 2016
Mon, September 12, 2016
Fri, September 9, 2016
Thu, May 9, 2013
[ Thu, May 09th 2013 ] - Market Wire
Achieves Record Revenues
Wed, May 8, 2013
Tue, May 7, 2013
Mon, May 6, 2013
Sun, May 5, 2013
Fri, May 3, 2013
Thu, May 2, 2013
Wed, May 1, 2013
Tue, April 30, 2013
Mon, April 29, 2013
Sun, April 28, 2013
Fri, April 26, 2013
Thu, April 25, 2013
Wed, April 24, 2013
Tue, April 23, 2013

Insys Therapeutics Announces Pricing of Initial Public Offering


//health-fitness.news-articles.net/content/2013/ .. nnounces-pricing-of-initial-public-offering.html
Published in Health and Fitness on Thursday, May 2nd 2013 at 6:30 GMT by Market Wire   Print publication without navigation


May 02, 2013 09:11 ET

Insys Therapeutics Announces Pricing of Initial Public Offering

PHOENIX, AZ--(Marketwired - May 2, 2013) -  Insys Therapeutics, Inc. (NASDAQ: [ INSY ]), a specialty pharmaceutical company that develops and commercializes innovative supportive care products, today announced the pricing of its initial public offering of four million shares of its common stock at a price to the public of $8.00 per share. The shares of Insys' common stock will trade on the NASDAQ Global Market under the symbol "INSY." All of the shares of common stock are being offered by Insys. In addition, the company has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the initial public offering price to cover over-allotments, if any.

Wells Fargo Securities, LLC and JMP Securities LLC are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as co-manager.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A registration statement relating to the offering has been filed with, and declared effective by, the Securities and Exchange Commission. The offering is being made only by means of a final prospectus, which is part of the effective registration statement. Copies of the final prospectus, when available, may be obtained by contacting Wells Fargo Securities, LLC, 1525 West W.T. Harris Boulevard, NC0675, Charlotte, NC 28262, Attn: Capital Markets Client Support, telephone: 1-800-326-5897 or email: [ cmclientsupport@wellsfargo.com ]; or JMP Securities, Attn: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111 (415-835-8985).

About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. We have two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. We market Subsys through our incentive-based, cost-efficient commercial organization of approximately 67 sales professionals. Our lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved.



Publication Contributing Sources